Product News Archives | Page 2 of 8 | Aurobindo Pharma USA

Currently Browsing

All Product News

January 10, 2023


Aurobindo Receives FDA Approval for Emzahh (Norethindrone Tablets USP), 0.35mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Emzahh (Norethindrone Tablets USP), 0.35mg. Aurobindo Pharma’s Emzahh (Norethindrone Tablets USP), are an AB-rated generic equivalent to the reference listed drug (RLD), ORTHO MICRONOR® Tablets manufactured by Janssen Pharmaceuticals Inc.  Emzahh (Norethindrone Tablets USP) are indicated […]

January 09, 2023


Aurobindo Receives FDA Approval for Lacosamide Tablets 50mg, 100mg, 150mg, & 200mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Lacosamide Tablets USP, 50mg, 100mg, 150mg and 200mg. Aurobindo Pharma’s Lacosamide Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), VIMPAT® Tablets manufactured by UCB, Inc.  Lacosamide Tablets are […]

January 09, 2023


Aurobindo Receives FDA Approval for Dimethyl Fumarate Delayed-Release Capsules, 120mg and 240mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Dimethyl Fumarate Delayed-Release Capsules, 120mg and 240mg. Aurobindo Pharma’s Dimethyl Fumarate Delayed-Release Capsules, are an AB-rated generic equivalent to the reference listed drug (RLD), TECFIDERA® Delayed-Release Capsules manufactured by BIOGEN Inc. Dimethyl […]

January 03, 2023


Aurobindo Receives FDA Approval for Sildenafil for Oral Suspension, 10mg/mL

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Sildenafil for Oral Suspension, 10mg/mL. Aurobindo Pharma’s Sildenafil for Oral Suspension, are an AB-rated generic equivalent to the reference listed drug (RLD), Revatio® for oral suspension 10mg/mL manufactured by Viatris Specialty LLC.  […]

January 03, 2023


Aurobindo Receives FDA Approval for Ranolazine ER Tablets 500mg and 1000mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Ranolazine Extended-Release Tablets, 500mg and 1000mg. Aurobindo Pharma’s Ranolazine Extended-Release Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), RANEXA® Extended-Release Tablets, manufactured by Gilead Sciences Inc. Ranolazine Extended-Release […]

January 03, 2023


Aurobindo Receives FDA Approval for Solifenacin Succinate Tablets, 5mg and 10mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Solifenacin Succinate Tablets, 5mg, and 10mg. Aurobindo Pharma’s Solifenacin Succinate Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), VESIcare® Tablets, manufactured by Astellas Pharma US, Inc. Solifenacin Succinate […]

November 30, 2022


Aurobindo Receives FDA Approval for Ursodiol Capsules USP, 300mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Ursodiol Capsules USP, 300mg. Aurobindo Pharma’s Ursodiol Capsules, are an AB-rated generic equivalent to the reference listed drug (RLD), Actigall® Capsules, manufactured by Teva Branded Pharmaceutical Products R&D, Inc. Ursodiol Capsules are […]

November 29, 2022


Aurobindo Receives FDA Approval for Carbidopa and Levodopa Tablets

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Carbidopa and Levodopa Tablets USP, 10mg/100mg, 25mg/100mg, and 25mg/250mg. Aurobindo Pharma’s Carbidopa and Levodopa Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), SINEMET® Tablets, manufactured by ORGANON, LLC. Carbidopa […]

November 29, 2022


Aurobindo Receives FDA Approval for Valganciclovir for Oral Solution, 50mg/mL

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Valganciclovir for Oral Solution, 50mg/mL. Aurobindo Pharma’s Valganciclovir for Oral Solution, are an AB-rated generic equivalent to the reference listed drug (RLD), VALCYTE® for oral solution 50mg/1mL, manufactured by HOFFMANN LA ROCHE […]

October 24, 2022


Aurobindo Pharma USA, Inc. Initiates Voluntary Nationwide Recall of Two (2) Lots of Quinapril and Hydrochlorothiazide Tablets USP 20mg/12.5mg, due to the detection of N-Nitroso Quinapril Impurity.

Aurobindo Pharma USA, Inc.: Contact 1-866-850-2876 (Option 2) Recall being handled by Qualanex: Contact 1-888-504-2014 FOR IMMEDIATE RELEASE – October 28, 2022– East Windsor, New Jersey, Aurobindo Pharma USA, Inc. has initiated a voluntary recall of two (2) lots (refer table below) of combination project, Quinapril and Hydrochlorothiazide Tablets USP 20mg / 12.5mg, to the […]

September 26, 2022


Aurobindo Receives FDA Approval for Dicloxacillin Sodium Capsules USP, 250mg and 500mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Dicloxacillin Sodium Capsules USP, 250mg and 500mg. Aurobindo Pharma’s Dicloxacillin Sodium Capsules are an AB-rated generic equivalent to the reference listed drug (RLD), Pathocil® Capsules, manufactured by Wyeth Ayerst Laboratories. Dicloxacillin Sodium […]

May 23, 2022


Aurobindo Receives FDA Approval for Exemestane Tablets USP, 25 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Exemestane Tablets USP, 25 mg.  Aurobindo Pharma’s Exemestane Tablets are an AB-rated generic equivalent to the reference listed drug (RLD), AROMASIN® tablets, manufactured by Pfizer Inc, USA.   Exemestane Tablets are indicated for: […]